VOR (Very High Frequency Omni-Directional Range) stations are ground-based navigation aids that use radio signals to guide aircraft, serving as a backup to GPS. While many VORs are being ...

The average one-year price target for Vor Biopharma (NasdaqGS:VOR) has been revised to $36.46 / share. This is an increase of ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose ...

Vor Biopharma Inc. (VOR) closed the last trading session at $5.39, gaining 6.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Vor Biopharma (NASDAQ:VOR) stock is up 116% in the last year, providing strong gains for shareholders.

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.

According to the prospectus, Vor Biopharma will not receive any proceeds from the sale of shares by the selling stockholders, though the company would receive proceeds from any warrants exercised for ...

Vor Biopharma (NASDAQ:VOR) has filed a prospectus to register 51M shares of common stock for potential resale by existing stockholders. Includes: 16M shares issuable under a warrant granted to RemeGen ...

BOCA RATON, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (Nasdaq: VOR), a clinical-stage ...

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of ...